Kates R E, Harrison D C, Winkle R A
Clin Pharmacol Ther. 1982 Apr;31(4):427-32. doi: 10.1038/clpt.1982.55.
Cumulation of encainide and its major metabolites, O-demethylencainide (ODE), 3-methoxy-ODE (MODE), and N-demethylencainide (NDE) was examined in patients with frequent complex ventricular ectopy. After 6 mo on encainide patients were admitted to Stanford University Hospital and the drug was discontinued for 24 hr. During this time blood samples were drawn to characterize the cumulation and disposition of the drug and metabolites. The mean steady-state concentrations of encainide, ODE, and MODE were 56.3, 214.6, and 184.6 ng/ml after doses ranging from 100 to 250 mg/day. The concentration ratios of ODE/encainide and MODE/encainide were 5.02 +/- 2.61 and 5.15 +/- 4.13. NDE was detected in the plasma of only one patient. Elimination half lifes of encainide and ODE were 1.16 +/- 0.5 and 11.41 +/- 9.58 hr. MODE disappeared slowly and at 24 hr the plasma concentration was still 59.8 +/- 39.9% of its mean steady-state concentration. Our data indicate that the metabolites of encainide cumulate in the plasma of patients on long-term oral therapy and must be considered when evaluating its clinical efficacy.
在频发复杂性室性早搏患者中研究了恩卡胺及其主要代谢产物O-去甲基恩卡胺(ODE)、3-甲氧基-O-去甲基恩卡胺(MODE)和N-去甲基恩卡胺(NDE)的蓄积情况。恩卡胺治疗6个月后,患者入住斯坦福大学医院,停药24小时。在此期间采集血样,以表征药物及其代谢产物的蓄积和处置情况。在每日剂量为100至250毫克的情况下,恩卡胺、ODE和MODE的平均稳态浓度分别为56.3、214.6和184.6纳克/毫升。ODE/恩卡胺和MODE/恩卡胺的浓度比分别为5.02±2.61和5.15±4.13。仅在一名患者的血浆中检测到NDE。恩卡胺和ODE的消除半衰期分别为1.16±0.5小时和11.41±9.58小时。MODE消失缓慢,在24小时时血浆浓度仍为其平均稳态浓度的59.8±39.9%。我们的数据表明,恩卡胺的代谢产物在长期口服治疗患者的血浆中蓄积,在评估其临床疗效时必须予以考虑。